In this report, RFA initially enhanced a strong T-cell-mediated immune response in the tumor, and the tumor quickly overcame the immune responses by inhibiting the function of CD8+ and CD4+ T cells, driving a shift to higher regulatory T-cells and upregulating PD-L1/PD-1 expression. This evidence concerns the gene CD8A and neoplasm.